Within 5 days, this university in Liaoning published 2 papers, providing new ideas for cancer treatment and tumor vaccine research and development

In April 2021, China Medical University School of Pharmacy Guo Feng, Wei Minjie, and Associate Professor Yu Zhaojin successively published tumor-related research papers in the internationally renowned journal Autophagy and the international authoritative journal Journal of Hematology & Oncology, showing the latest The research results provided new ideas for the clinical treatment of pancreatic cancer and the development of therapeutic vaccines for tumors.

Wei Minjie/Yu Zhaojin's research group has made new progress in the field of novel tumor therapeutic epitope peptide vaccines

On April 28, 2021, Wei Minjie/Yu Zhaojin's research group from the School of Pharmacy, China Medical University, in the Journal of Hematology & Oncology (Impact Factor Published the article "HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumor vaccine". Associate Professor Yu Zhaojin, Liu Wensi doctoral student and He Ying doctoral student are the co-first authors of the paper , Professor Wei Minjie, Li Jianping and Zhang Rui are the co-authors , China Medical University School of Pharmacy It is the first unit to complete the thesis.

Wei Minjie/Yu Zhaojin's research group has been committed to the research of novel tumor therapeutic vaccines based on tumor antigen dominant CTL epitope peptides. This research focuses on the screening of new tumor antigen peptide LA, the evaluation of vaccine immune anti-tumor activity and the study of immune activation mechanism. The ECM1 protein-derived HLA-A2.1 restricted dominant CTL epitope peptide LA and its induced DC were reported for the first time. -CTL and DC-NK dual immune anti-tumor effect, revealing that vaccine LA activates CD8+ T cells through cross-presentation of dendritic cells (DCs) intracellular vacuolar pathway, and activates TLR4 receptor signaling on the surface of DCs to increase MICA/ B expresses and activates NK cells, a new dual immune activation mechanism.

Traditional tumor therapeutic vaccines only focus on how to enhance the activity of CD8+ T cells. The results of this study improved the strategy, seeking to enhance the immune activity of both CD8+ T cells and NK cells, significantly improving the anti-tumor effect of the vaccine and improving the therapeutic effect of tumors. The development of vaccines provides new ideas and new tools.

Guo Feng-Wang Wuyang joint team found that targeting lysosome ion channel can treat pancreatic cancer

April 23, 2021, Professor Guo Feng, Department of Drug Toxicology, School of Pharmacy, China Medical University-Xuzhou Medical UniversityJiangsu The joint research team of Professor Wang Wuyang from the Provincial Key Laboratory of Anesthesiology published a research paper titled "MCOLN1/TRPML1 finely controls oncogenic autophagyin cancer by mediating zinc influx" in the well-known journal Autophagy (2019 IF: 9.77). Professor Guo Feng from the School of Pharmacy, China Medical University, and Professor Wang Wuyang from Xuzhou Medical University are the co-corresponding authors.

Researchers found that activation of a non-selective cation channel TRPML1 on the lysosomal membrane can specifically inhibit the autophagy activity of tumor cells, clarifying that TRPML1 regulates the autophagy activity of tumor cells through its This is accomplished by mediating the release of zinc ions from the lysosomal pool. After the activation of TRPML1 channel, zinc ions in lysosomes are released to cytoplasm , and the zinc ions released into the cytoplasm inhibit the binding of two SNARE proteins, syntaxin17 and VAMP8, thereby hindering autophagosome The fusion process with lysosome finally inhibits the autophagy activity of tumor cells.

TRPML1 inhibits autophagy by inducing apoptosis , cell cycle inhibition, effectively preventing the growth of xenografted human pancreatic cancer in mice, and greatly extending the lifespan of xenografted pancreatic cancer mice. This study clarifies the molecular mechanism of TRPML1 channel regulating the autophagy process of tumor cells. Targeted activation of TRPML1 can effectively inhibit the growth of pancreatic cancer by inhibiting the autophagy activity of tumor cells, providing a new therapeutic idea for clinical treatment of pancreatic cancer.

Follow the headline number "China Medical University Recruitment Office" to get more exciting information.

Source: School of Pharmacy, China Medical University, Cancer Medicine Network